Key Highlights

  • Onconetix (NASDAQ:ONCO) is listed at USD 0.57, which is -2% above its 52-week low of USD 0.58 and 99.7% below its high of USD 209.50.
  • Onconetix completed a 1-for-5 reverse split on March 25 and a 1-for-10 reverse split on May 21, 2026, cutting shares outstanding from about 11.4 million to about 1.14 million in the second split.
  • Stockholders on April 30 approved further splits with an aggregate cap of 1-for-100, and the company owns Proclarix, a blood test for prostate cancer.
  • A multi-center Proclarix study with Labcorp began in May, while the stock fell 3.61% to USD 0.57, below its USD 0.58 listed low, on a market value of USD 3.43 million.

The Latest Verified Updates

No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Onconetix is a Cincinnati-based commercial-stage biotechnology company that owns Proclarix, an in vitro diagnostic blood test used with PSA to identify clinically significant prostate cancer, through its Swiss subsidiary Proteomedix. It carried out a 1-for-5 reverse split effective March 25 and a 1-for-10 reverse split effective May 21, 2026, both to maintain Nasdaq's USD 1.00 minimum bid price, and stockholders approved further reverse splits up to 1-for-100 in aggregate. On May 13 it reported two peer-reviewed Proclarix papers and the start of a multi-center clinical study with Labcorp.

Why Trading Is Heavy and What the Data Says

The May split reduced outstanding shares from about 11.4 million to about 1.14 million, and the March split reduced them from about 3.6 million to about 0.7 million, which shows heavy share creation between splits. The 52-week range from USD 0.58 to USD 209.50 shows the stock is trading at a new low after a decline of more than 99% from the adjusted high. At the USD 3.43 million market value, even a small financing could double the share count. Simple arithmetic puts the prior close near USD 0.59, so the day's move is about USD 0.02 a share. The price sits -2% above its 52-week low and 99.7% below its high, which frames how much of the range has already been used. The screen shows volume of 46.293 million shares against a three-month average of 2.232 million, or 20.7 times, and arithmetic on that volume implies traded value of about USD 26.4 million, or 7.7 times the market value. Identical volume figures have appeared on several earlier screens, so treat the field as carried over and rely on the drivers above for why the stock is active.

Risks and What to Watch

A shrinking price despite two reverse splits points to heavy dilution, and the diagnostic is still small. What to watch next: new share issuance, Labcorp study progress and Nasdaq compliance. This is information only and not investment advice.

Where Things Stand

Market conditions frame the day: oil traded above USD 100, the big banks report this week and speculative technology names were under pressure. Onconetix (NASDAQ:ONCO) is moving with repeated reverse splits and persistent dilution. A drop on a stock this small and this volatile can reverse quickly, so the balance of evidence favors waiting for confirmation from filings and the next session. Direction remains unknown, and the next catalyst is new share issuance, Labcorp study progress and Nasdaq compliance. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.